Article

Generic version of OAB drug now available

A generic version of the overactive bladder drug trospium chloride has received FDA approval and is now available.

A generic version of the overactive bladder drug trospium chloride has received FDA approval and is now available.

Perrigo Co. said it had previously prevailed in litigation related to the drug’s launch at both the district and appellate levels. The product has begun shipping immediately, according to the company.

Trospium, also marketed under the brand name Sanctura XR, is a once-daily medication for the treatment of OAB with symptoms of urge urinary incontinence, urgency, and urinary frequency.

Related Content

PTNS therapy for OAB found durable at 3 years

 

Newer overactive bladder agent viable alternative to antimuscarinics

Related Videos
Anna Myers, CNP, answers a question during a Zoom video interview
Vanita Gaglani, RPT, answers a question during a video interview
J. Quentin Clemens, MD, MSCI, answers a question during a video interview
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
A. Lenore Ackerman, MD, PhD, answers a question during a Zoom video interview
Hospital waiting room with reception counter at medical facility | Image Credit: © visoot - stock.adobe.com
A. Lenore Ackerman, MD, PhD, answers a question during a Zoom video interview
Christian Moro, PhD, BSc, BEd, MBus, SFHEA, answers a question during a Zoom video interview
Related Content
FDA updates in urology: April 2025
May 1st 2025

FDA updates in urology: April 2025

Hannah Clarke
A recap of the FDA submissions and regulatory decisions in urology from April 2025.
Key updates from the AUA/ASRM male infertility guideline amendment
September 23rd 2024

Key updates from the AUA/ASRM male infertility guideline amendment

Urology Times staff
In this episode, Robert E. Brannigan, MD, and Juan J. Andino, MD, MBA, discuss the recent amendment to the AUA/ASRM guideline on male infertility.
Key FDA decisions urologists can expect in the first half of 2025
January 28th 2025

Key FDA decisions urologists can expect in the first half of 2025

Hannah Clarke
Check out the key regulatory decisions set to happen early this year.
Destigmatizing Urology: Dr. Winter discusses STDs/STIs
March 22nd 2022

Destigmatizing Urology: Dr. Winter discusses STDs/STIs

Urology Times staff
“We need to just approach STIs as the medical conditions they are because until we do, and until we take those stigmas away, people will truly have resistance to discussing it, hesitance to discussing it, and resistance to diagnosis and intervention,” says Ashley Winter, MD.
In-depth study of microbiomes may lead to better UTI care for patients with spina bifida
January 6th 2025

In-depth study of microbiomes may lead to better UTI care for patients with spina bifida

Brendan T. Frainey, MD
"The goal for this study was to understand, over the lifetime in individuals with spina bifida, what bacteria are present in their urine normally, what bacteria are present when they have a UTI, and what are some important clinical differences we can tease out to help understand which patients should really be treated," says Brendan T. Frainey, MD.
FDA logo
January 1st 2025

2024 Urology Times pipeline report

Jason M. Broderick Hannah Clarke Brittany Lovely
Catch up on all the notable drug and device approvals in urology over the past year.
© 2025 MJH Life Sciences

All rights reserved.